8-K: Amicus Therapeutics Announces 15% Revenue Growth in Q1 2025, Expands Portfolio with DMX-200 In-Licensing

Amicus Therapeutics reports a 15% year-over-year revenue increase in Q1 2025 and expands its portfolio by in-licensing DMX-200 for rare kidney disease.

Summary

• Amicus Therapeutics announced its financial results for the first quarter ended March 31, 2025.
• Total revenues for Q1 2025 were $125.2 million, a 15% increase year-over-year at constant exchange rates (CER).
• Galafold net product sales were $104.2 million, a 5% increase (6% at CER).
• Pombiliti + Opfolda net product sales were $21.0 million, a 90% increase (92% at CER).
• The company is adjusting its 2025 revenue growth guidance for Pombiliti + Opfolda to +50-65% at CER.
• GAAP net loss was $21.7 million, or $0.07 loss per share, compared to a net loss of $48.4 million, or $0.16 per share, for Q1 2024.
• Non-GAAP net income was $9.0 million, or $0.03 per share, compared to a non-GAAP net loss of $4.6 million, or $0.02 per share, for Q1 2024.
• Cash, cash equivalents, and marketable securities totaled $250.6 million at March 31, 2025.
• Amicus has licensed exclusive rights for the U.S. commercialization of Dimerix's DMX-200, a Phase 3 treatment for FSGS.
• The company anticipates surpassing $1 billion in total sales in 2028.
• GAAP profitability is still expected during the second half of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the revenue growth and strategic in-licensing, but tempered by the adjusted guidance for Pombiliti + Opfolda and the GAAP net loss. The company's outlook for profitability and long-term growth contributes to the positive sentiment.

Positives

• Total revenue increased by 15% year-over-year at CER, reaching $125.2 million.
• Galafold sales increased by 5% (6% at CER) to $104.2 million, driven by strong patient demand.
• Pombiliti + Opfolda sales increased by 90% (92% at CER) to $21.0 million.
• The company is on track to achieve GAAP profitability during the second half of 2025.
• Amicus secured an exclusive U.S. licensing agreement for DMX-200, a Phase 3 program for FSGS.
• Non-GAAP net income was $9.0 million, or $0.03 per share, compared to a non-GAAP net loss of $4.6 million, or $0.02 per share, for Q1 2024.

Negatives

• The company experienced a currency headwind of $1.4 million or 1%.
• Galafold sales were partially offset by order timing and higher than anticipated VPAG rebate in the U.K.
• The company is adjusting its 2025 revenue growth guidance for Pombiliti + Opfolda to +50-65% at CER, down from 65-85%.
• GAAP net loss was $21.7 million, or $0.07 loss per share.

Risks

• Regulatory authorities may not grant or may delay approval for product candidates.
• Required regulatory inspections may be delayed or not be successful, delaying or preventing product approval.
• The company may not be successful in negotiations with pricing and reimbursement authorities.
• The company may not be successful in commercializing Galafold and/or Pombiliti and Opfolda in Europe, the UK, the US and other geographies.
• The Dimerix collaboration and license agreement for DMX-200 may not be successful.
• The company may not be able to manufacture or supply sufficient commercial products.
• The company may need additional funding to complete the manufacturing and commercialization of its products.
• Market factors and the company's ability to execute its operational and budget plans could impact financial goals.

Future Outlook

Amicus expects to achieve GAAP profitability during the second half of 2025 and anticipates surpassing $1 billion in total sales in 2028. The company aims for double-digit revenue growth and is focused on advancing studies in Fabry, Pompe, and FSGS.

Management Comments

• Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated that the underlying patient demand observed in Q1 will drive robust growth for Galafold, and the company continues to expect accelerating Pombiliti + Opfolda sales as the year progresses.
• Mr. Campbell also mentioned the in-licensing of Dimerix DMX-200, highlighting its potential as a first-in-class treatment for FSGS and its alignment with the company's strategy to leverage its rare disease commercial infrastructure.

Industry Context

The announcement reflects the ongoing growth in the rare disease market, with Amicus strategically expanding its portfolio through in-licensing to address unmet medical needs. The focus on achieving profitability and leveraging existing commercial infrastructure aligns with industry trends of sustainable growth and efficient operations.

Comparison to Industry Standards

• Amicus's growth in Galafold sales is comparable to other companies in the rare disease space with established therapies, such as BioMarin's growth with Vimizim and Naglazyme.
• The Pombiliti + Opfolda growth rate is significantly higher than the average for enzyme replacement therapies, indicating a strong market uptake.
• The in-licensing of DMX-200 is similar to strategic moves by companies like Alexion (now part of AstraZeneca) to expand their pipeline through acquisitions and licensing agreements.
• The target of $1 billion in total sales by 2028 is an ambitious goal, comparable to the revenue targets set by other mid-sized biotech companies focused on rare diseases.

Stakeholder Impact

• Shareholders can expect potential value creation through revenue growth and pipeline expansion.
• Patients with Fabry disease and Pompe disease will benefit from continued access to Galafold and Pombiliti + Opfolda.
• Patients with FSGS may benefit from a potential new treatment option with DMX-200.
• Employees will have opportunities for growth and development within the expanding company.
• The company's commitment to GAAP profitability in H2 2025 will benefit creditors and investors.

Next Steps

• Continue commercialization of Galafold and Pombiliti + Opfolda in existing and new markets.
• Advance the Phase 3 clinical trial of DMX-200 for FSGS.
• Pursue regulatory approvals for Pombiliti + Opfolda in Japan and other countries.
• Expand the supply chain for Pombiliti through the agreement with Sharp Sterile Manufacturing.

Key Dates

Keywords

Amicus Therapeutics, Galafold, Pombiliti, Opfolda, DMX-200, FSGS, Rare Diseases, Financial Results, Revenue Growth, GAAP Profitability